Serious psoriatic arthritis; Pain in joints of hands and knees; This case was reported by a other health professional via other manufacturer and described the occurrence of psoriatic arthritis in a 52-year-old female patient who received HAB (Twinrix) for prophylaxis.   Co-suspect products included hepatitis A and hepatitis B vaccine pre-filled syringe device (Twinrix Pre-Filled Syringe Device) injection syringe for prophylaxis, DTPa (Reduced antigen) (Boostrix) for prophylaxis, MEASLES MUMPS RUBELLA VACCINE for prophylaxis and TYPHOID VACCINE (TYPHIM VI) (batch number R2A251M, expiry date 11th May 2021) for prophylaxis.   On 11th December 2019, the patient received Twinrix and Twinrix Pre-Filled Syringe Device. On 9th December 2019, the patient received Boostrix. On 11th December 2019, the patient received MEASLES MUMPS RUBELLA VACCINE. On 9th December 2019, the patient received TYPHIM VI (intramuscular) .5 ml. On 18th December 2019, 7 days after receiving Twinrix and Twinrix Pre-Filled Syringe Device and 9 days after receiving Boostrix, the patient experienced psoriatic arthritis (serious criteria GSK medically significant and other: Serious by reporter) and joint pain. On an unknown date, the outcome of the psoriatic arthritis and joint pain were not recovered/not resolved.   It was unknown if the reporter considered the psoriatic arthritis and joint pain to be related to Twinrix, Twinrix Pre-Filled Syringe Device and Boostrix.This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The patient's medical history, medical treatment, vaccination and family history were not provided. The patient experienced pain in her joints of both hands and both knees and psoriatic arthritis while receiving vaccines Measles vaccine, Mumps vaccine, Rubella vaccine (MMR), Hepatitis A vaccine inact , Heaptitis B vaccine RHBSAG (Yeast) (Twinrix), Diptheria vaccine Toxoid, Pertussis vaccine Acellular 3- component. Tetanus vaccine Toxoid (Boostrix) and Typhoid VI Poly saccharide Vaccine (TYPHIM VI). On 18th December 2019, 7 days after receiving Measles Mumps Rubella Vaccine, the patient experienced joint pain and psoriatic arthritis respectively. On 18th December 2019, 9 days after receiving Typhim VI vaccine, the patient experienced joint pain and psoriatic arthritis respectively. It was unknown if the reporter considered the psoriatic arthritis and joint pain to be related to Measles Mumps Rubella Vaccine. It was unknown if the reporter considered the psoriatic arthritis and joint pain to be related to Typhim VI Vaccine. It was not reported if patient received a corrective treatment for the events (arthralgia, psoriatic arthropathy). No new information reported. Additional information received from nurse on 8th March 2022, a new serious event psoriatic arthritis was added and case was updated from non serious to serious unsolicited non literature case. Narrative was amended accordingly. It was reported that nurse practitioner wants to report the consumer was newly diagnosed with Psoriatic arthritis and thought it was related to the vaccine received in 2019.